Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
出版年份 2021 全文链接
标题
Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
作者
关键词
-
出版物
npj Schizophrenia
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-12-09
DOI
10.1038/s41537-021-00190-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Management of Cardiovascular Health in People with Severe Mental Disorders
- (2021) Cédric Lemogne et al. Current Cardiology Reports
- Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
- (2021) Veronica Begni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
- (2021) Seth C. Hopkins et al. Translational Psychiatry
- Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
- (2020) Michelle Kokkinou et al. MOLECULAR PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
- (2017) Seth C Hopkins et al. SCHIZOPHRENIA BULLETIN
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
- (2017) Christoph U. Correll et al. World Psychiatry
- The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
- (2015) Marc De Hert et al. CNS DRUGS
- Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
- (2013) Antony Loebel et al. SCHIZOPHRENIA RESEARCH
- Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics
- (2012) Florent G. Revel et al. BIOLOGICAL PSYCHIATRY
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Brain-Specific Overexpression of Trace Amine-Associated Receptor 1 Alters Monoaminergic Neurotransmission and Decreases Sensitivity to Amphetamine
- (2012) Florent G Revel et al. NEUROPSYCHOPHARMACOLOGY
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- (2012) Masaaki Ogasa et al. PSYCHOPHARMACOLOGY
- The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
- (2011) Kelly Posner et al. AMERICAN JOURNAL OF PSYCHIATRY
- TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity
- (2011) F. G. Revel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder
- (2010) Brent T Mausbach et al. BIPOLAR DISORDERS
- The Brief Negative Symptom Scale: Psychometric Properties
- (2010) Brian Kirkpatrick et al. SCHIZOPHRENIA BULLETIN
- Lurasidone in the Treatment of Acute Schizophrenia
- (2009) Mitsutaka Nakamura et al. JOURNAL OF CLINICAL PSYCHIATRY
- The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system
- (2009) A. Bradaia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Psychiatric Comorbidities and Schizophrenia
- (2008) P. F. Buckley et al. SCHIZOPHRENIA BULLETIN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More